ACS is an umbrella term encompassing ST-elevation myocardial infarction, non-ST-elevation myocardial infarction, and unstable angina. Current drug targets for ACS, particularly those in the acute setting, include the molecular components of platelet aggregation, coagulation, and fibrinolysis. Posthospital management of ACS is targeted at reducing the incidence of recurrent thrombotic events, preventing adverse cardiac remodeling, and prolonging survival. Here we show how ACS is currently being treated and what drives the choice of pharmacotherapy for ACS patients in both the acute hospital and the 12-month posthospital settings, from the initiation of therapy, through to further lines of treatment.
- Which drugs are mostcommonly used to treat ACS patients in the acute and 12-month posthospital setting?
- What is the ADP receptor antagonist of choice in ACS and what is the most important driver behind this choice?
- Does switching between oral ADP receptor antagonists for ACS take place and what are the most common switching patterns?
- What are the cardiologist-reported factors determining current prescribing patterns for ACS and recent/anticipated changes?
Markets covered: United States
Methodology: Survey of 51 interventional and 49 non-interventional cardiologists in the United States, completed in January 2018.
Indication coverage: acute coronary syndrome
Key drugs covered: Brilinta, Effient, Zontivity, clopidogrel, Praluent, Repatha, bivalirudin, heparins, GP IIb/IIIa antagonists, ACE inhibitors, ARBs, beta blockers, and statins.
Key companies mentioned: AstraZeneca, Amgen, Sanofi, Regeneron, Eli Lilly, Chiesi, The Medicines Company, Roche, Janssen, Merck, and Medicure.
- Acute Coronary Syndrome - Current Treatment - Detailed, Expanded Analysis (US)
Author(s): Dominika Rudnicka-Noulin, PhD, MSc
Dominika Rudnicka-Noulin, PhD, MSc is a senior business insights analyst in the Cardiovascular, Metabolic and Renal division at Decision Resources Group, specializing in cardiovascular diseases, with expertise in heart failure and acute coronary syndrome.
Prior to joining DRG, Dominika held a position of an associate editor at Nature Communications, working across a variety of therapy areas. Dominika also worked for three years as a Postdoctoral Research Associate on a joint project between Imperial College London and MedImmune aimed at developing more potent antibody-based drugs. Dominika gained her PhD at the Institut Pasteur in Paris, France where her work was funded by the European Commission Marie Skłodowska-Curie Actions